Lexeo reports FY2025 net loss $100M; cash $246.6M, runway into 2028; LX2006 pivotal trial on track for 1H2026

Lexeo Therapeutics, Inc.

Net loss FY2025 $100.0M ($1.86/share) vs $98.3M ($3.09/share) in FY2024; Q4 loss $20.9M ($0.27).
R&D expenses FY2025 $63.8M vs $74.1M in FY2024; G&A $45.5M vs $31.7M.
Cash $246.6M as of Dec 31, 2025, expected to fund operations into 2028.
LX2006 for FA: FDA feedback on SUNRISE-FA 2 pivotal protocol expected Q2 2026; trial start 1H 2026.
Collaboration with Johnson & Johnson for targeted cardiac AAV delivery; new CMO Dr. Narinder Bhalla appointed.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lexeo Therapeutics, Inc. reported financial results for the fourth quarter and full year 2025.

Period: the fourth quarter and full year 2025
Result: reported results

Exact text from the filing

On March 30, 2026, Lexeo Therapeutics, Inc. (the “ Company ”) issued a press release announcing business highlights and its financial results for the three and twelve months ended December 31, 2025.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Lexeo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-131792

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.